Clinical trials: Recurrent Prostate Carcinoma
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate…
- Trial name
- SABRE (NCT05407311)
- Testing
- 64Cu-SAR-BBN
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC)
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate…
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
- Trial name
- NCT03460977
- Testing
- Mevrometostat (PF-06821497), Enzalutamide, Itraconazole
- Where
- 85 sites in United States, Bulgaria and 6 more
- Volunteers
- 453 people
- Sponsor
- Pfizer
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Prostate Cancer
Open Label Trial to Assess Iressa in Prostate Cancer Patients
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
- Trial name
- NCT00635856
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Prostate Cancer
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a…
- Trial name
- NCT00514072
- Testing
- BCG vaccine, prostate cancer vaccine ONY-P1
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Kael-GemVax Co., Ltd.
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Prostate Cancer
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce…
- Trial name
- NCT06496256
- Testing
- Barrigel, Transrectal Ultrasound
- Where
- 13 sites in United States, Australia
- Volunteers
- 84 people
- Sponsor
- Palette Life Sciences, Inc.
Prostate Cancer
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Inserting the gene for interleukin-2 into a person's prostate cancer cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00005072
- Testing
- Leuvectin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vical
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure
Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy
To assess by MR Imaging the lesions induced by WST09-mediated photodynamic therapy (PDT) in patients with recurrent or persistent localized prostate cancer following definitive radiotherapy using different light doses and…
- Trial name
- NCT00308919
- Testing
- WST09
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- STEBA France
Prostate Cancer
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004026
- Testing
- CT-2584, chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- CTI BioPharma
Prostate Cancer (Adenocarcinoma)
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time.
- Trial name
- NCT06655064
- Testing
- None- Observational
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Prospective Prolaris Value and Efficacy
This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
- Trial name
- P-PROVE (NCT03152448)
- Testing
- Prolaris
- Where
- 12 sites in United States
- Volunteers
- 1,511 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer.
- Trial name
- NCT00005947
- Testing
- sipuleucel-T
- Where
- 34 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dendreon
Biochemically Recurrent Prostate Cancer
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Researchers are looking for a better way to treat men who have biochemically recurrent hormone-naïve prostate cancer. Hormone-naïve prostate cancer is a prostate cancer that has not yet been treated with hormonal therapy…
- Trial name
- ARAMON (NCT05526248)
- Testing
- Darolutamide(BAY1841788, Nubeqa), Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Bayer
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb